Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has signed a contract with Liao Ning Yifan Pharmaceutical Co., Ltd. to acquire the marketing authorization for "Compound Dexamethasone Cream," which includes ownership of the drug formula, production process, technical secrets, and related patents and data [2][11]. Group 1: Transaction Overview - The company has entered into a technology transfer contract to acquire the marketing authorization for "Compound Dexamethasone Cream" [2]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it is within the approval authority of the chairman, thus not requiring board or shareholder approval [2]. - The transfer fee is structured in three phases, with 30% payable within five working days of signing, another 30% upon completion of production site change, and 40% after receiving the approval notice from the drug review center [8]. Group 2: Market Situation - There are 103 companies in China that have obtained production licenses for "Compound Dexamethasone Cream" [3]. - The sales figures for the cream in physical pharmacies were 175 million yuan in the first half of 2025 and projected to reach 429 million yuan in 2024 [3]. - The global market sales for dexamethasone formulations were approximately $1.198 billion in 2022 and $1.203 billion in 2023 [3]. Group 3: Impact on the Company - The acquisition aligns with the company's strategy to become a health industry group focused on innovative traditional Chinese medicine, enhancing its product pipeline and potentially providing new profit growth points [11]. - The addition of this dermatological product category is expected to strengthen the company's market competitiveness and facilitate industry chain integration and expansion [11].

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug prescription, production process, technical secrets, related patents, and technical data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization is aligned with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing market competitiveness [1] Group 2: Product Expansion - Following the acquisition, the company's dermatological product category will be effectively expanded, with the potential for new profit growth through brand empowerment within the group [1]

公司确定"打造成为一家以中药创新药为核心的健康产业集团"的发展战略以来，持续加大研发投入，并 同步通过外购来储备具有发展潜力的产品，以丰富公司产品管线，从而加快发展步伐。本次受让完成 后，公司皮肤病药物品类得到有效扩充，后续通过集团的品牌赋能，有望为公司提供新的利润增长点。 本次受让药品上市许可符合公司发展战略，有利于推动产业链整合和扩张，提升公司的市场竞争力。 智通财经APP讯，方盛制药(603998.SH)发布公告，2025年9月30日，公司与亿帆药业签订了《技术转让 (技术秘密)合同》，决定受让其"复方醋酸地塞米松乳膏"药品上市许可(包括但不限于药品处方、生产工 艺、技术秘密、与标的品种相关的专利、技术资料等数据的所有权)。 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced on October 9 that it signed a technology transfer contract with Yifan Pharmaceutical on September 30, acquiring the marketing authorization for "Compound Dexamethasone Acetate Cream" [1] Group 1 - The acquired drug is indicated for localized pruritus, neurodermatitis, contact dermatitis, seborrheic dermatitis, and chronic eczema [1]

Core Viewpoint - The transaction between Fangsheng Pharmaceutical and Yifan Pharmaceutical involves the acquisition of the marketing authorization for "Compound Dexamethasone Acetate Cream," which is expected to enhance the company's product portfolio in dermatology and potentially serve as a new profit growth point [1] Group 1: Transaction Details - The contract was signed on September 30, 2025, and does not constitute a related party transaction or a major asset restructuring, falling within the chairman's approval authority [1] - The payment for the transaction will be made in three phases, indicating a structured financial approach to the acquisition [1] Group 2: Market Context - The drug is used for various skin diseases, with 103 companies in China holding production licenses for it [1] - In the first half of 2025, the sales revenue from physical pharmacies for this drug reached 175 million yuan, highlighting its market potential [1] Group 3: Strategic Implications - The acquisition aligns with the company's development strategy to expand its dermatological product offerings, which is expected to contribute positively to future revenue streams [1] - However, the timeline for completing the holder change procedures remains uncertain, and sales may be influenced by market factors, necessitating cautious decision-making by investors [1]

每经AI快讯，10月9日，方盛制药（603998）(603998.SH)公告称，方盛制药与辽宁亿帆药业签订《技术 转让（技术秘密）合同》，受让其"复方醋酸地塞米松乳膏"药品上市许可。该药品主要用于局限性搔痒 症、神经性皮炎等。交易金额在公司董事长审批权限范围内，无需经董事会、股东会审议批准。受让完 成后，公司皮肤病药物品类得到有效扩充，有望提供新的利润增长点。 ...

Core Viewpoint - The introduction of self-service medicine vending machines is raising concerns among traditional pharmacies about competition and regulatory compliance, particularly regarding the sale of prescription drugs [5][12][14]. Group 1: Market Trends and Data - The retail pharmacy sector is experiencing a decline in growth, with physical pharmacies projected to see a decrease of 0.4% from 2023 to 2024, following a drop of 0.9% from 2022 to 2023 [3]. - E-commerce B2C channels, including internet hospitals, are showing growth, with a 26.9% increase in 2022 compared to 2021, and an 18.8% increase in 2023 compared to 2022 [4]. - The self-service vending machines can hold over a thousand types of medications and are designed to meet the 24-hour medication needs of consumers, addressing the "last mile" issue in drug purchasing [5][7]. Group 2: Regulatory Environment - The Beijing regulations specify that self-service machines can only sell Class B non-prescription drugs (OTC), which has led to concerns about the potential for these machines to dispense prescription medications without proper oversight [9][10]. - The National Medical Products Administration has stated that self-service machines are not allowed to sell prescription drugs, emphasizing the need for regulatory compliance in the distribution of medications [13]. Group 3: Industry Concerns - Pharmacy operators are worried that self-service machines could operate without licensed pharmacists, leading to potential safety risks in medication dispensing [15][18]. - The operational costs for traditional pharmacies, including the need for licensed pharmacists, are significantly higher compared to the low overhead of self-service machines, which could create an uneven playing field [20][23]. - The rapid deployment of self-service machines could disrupt the traditional pharmacy model, as they can be set up quickly and at a lower cost compared to opening new physical locations [24][26]. Group 4: Economic Implications - The cost of maintaining a licensed pharmacist in a physical pharmacy can add approximately 20,000 yuan per month, while self-service machines do not incur such costs, leading to competitive disadvantages for traditional pharmacies [20][23]. - The profitability of self-service machines is questioned, as some operators report low revenue compared to the initial investment required for the machines [29][30]. - The potential for self-service machines to take over the market raises concerns about the sustainability of traditional pharmacies, especially in densely populated urban areas where competition is already fierce [34][35].